Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 regarding grant of Stock Options/ Units under 'WBL Employee Stock Option ....
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Windlas Biotech Limited has disclosed the grant of employee stock options to eligible employees. The Nomination and Remuneration Committee approved 15,750 options under the WBL Employee Stock Option Scheme 2023 (ESOS 2023) and 21,250 units under the Windlas Plan 2025, totaling 37,000 stock options. Under ESOS 2023, options can be exercised at a price with up to 25% discount from market price, with vesting over 1-4 years. Under Windlas Plan 2025, units are granted at face value of Rs. 5 per share, vesting in four equal installments over 48 months. Each option/unit entitles the holder to one fully paid-up equity share of face value Rs. 5 upon exercise. This disclosure complies with SEBI regulations for share-based employee benefits.
This is a routine corporate governance disclosure and has no direct impact on company revenue or operations. Shareholders should note potential dilution of equity as these options are exercised over time.